<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v2.3 20070202//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName journalpublishing.dtd?><?SourceDTD.Version 2.3?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 2?><front><journal-meta><journal-id journal-id-type="nlm-ta">Int J Mol Sci</journal-id><journal-id journal-id-type="iso-abbrev">Int J Mol Sci</journal-id><journal-id journal-id-type="publisher-id">ijms</journal-id><journal-title-group><journal-title>International Journal of Molecular Sciences</journal-title></journal-title-group><issn pub-type="epub">1422-0067</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">4200867</article-id><article-id pub-id-type="pmid">25162823</article-id><article-id pub-id-type="doi">10.3390/ijms150915011</article-id><article-id pub-id-type="publisher-id">ijms-15-15011</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title><SecTag type="TITLE"><text><SENT sid="0" pm="."><plain>MRC2 Expression Correlates with TGFβ1 and Survival in Hepatocellular Carcinoma </plain></SENT>
</text></SecTag></article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Gai</surname><given-names>Xiaohong</given-names></name><xref ref-type="author-notes" rid="fn1-ijms-15-15011">†</xref></contrib><contrib contrib-type="author"><name><surname>Tu</surname><given-names>Kangsheng</given-names></name><xref ref-type="author-notes" rid="fn1-ijms-15-15011">†</xref></contrib><contrib contrib-type="author"><name><surname>Lu</surname><given-names>Zhongtang</given-names></name></contrib><contrib contrib-type="author"><name><surname>Zheng</surname><given-names>Xin</given-names></name><xref rid="c1-ijms-15-15011" ref-type="corresp">*</xref></contrib></contrib-group><aff id="af1-ijms-15-15011">Department of Hepatobiliary Surgery, the First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, Shaanxi 710061, China; E-Mails: <email>xhgai.xjtu@gmail.com</email> (X.G.); <email>tks0912@foxmail.com</email> (K.T.); <email>paulzheng@stu.xjtu.edu.cn</email> (Z.L.)</aff><author-notes><fn id="fn1-ijms-15-15011"><label>†</label><p><text><SENT sid="1" pm="."><plain>These authors contributed equally to this work. </plain></SENT>
</text></p></fn><corresp id="c1-ijms-15-15011"><label>*</label>Author to whom correspondence should be addressed; E-Mail: <email>xin.zheng.xjtu@gmail.com</email>; Tel./Fax: +86-29-8532-3209.</corresp></author-notes><pub-date pub-type="epub"><day>26</day><month>8</month><year>2014</year></pub-date><pub-date pub-type="collection"><month>9</month><year>2014</year></pub-date><volume>15</volume><issue>9</issue><fpage>15011</fpage><lpage>15025</lpage><history><date date-type="received"><day>22</day><month>4</month><year>2014</year></date><date date-type="rev-recd"><day>10</day><month>7</month><year>2014</year></date><date date-type="accepted"><day>20</day><month>8</month><year>2014</year></date></history><permissions><copyright-statement>© 2014 by the authors; licensee MDPI, Basel, Switzerland.</copyright-statement><copyright-year>2014</copyright-year><license><license-p>This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/3.0/">http://creativecommons.org/licenses/by/3.0/</ext-link>).</license-p></license></permissions><abstract><p><SecTag type="ABS"><text><SENT sid="2" pm="."><plain>MRC2 (Mannose Receptor C Type 2) is a constitutively recycling endocytic receptor belonging to the mannose receptor family, which has been found to be closely involved with cancer metastasis. </plain></SENT>
<SENT sid="3" pm="."><plain>This study attempted to determine MRC2 expression on hepatocellular carcinoma (HCC) and its significance on postsurgical prognosis of HCCs. </plain></SENT>
<SENT sid="4" pm="."><plain>The expression of both MRC2 and transforming growth factor (TGFβ1) was detected in tumor tissues and adjacent liver tissues from 96 HCCs by immunohistochemistry staining, and it was found that MRC2 expression in HCC tissues was significantly higher than in adjacent liver tissues. </plain></SENT>
<SENT sid="5" pm="."><plain>HCCs with higher MRC2 expression had worse prognosis after liver resection. </plain></SENT>
<SENT sid="6" pm="."><plain>Univariate analysis showed that advanced TNM staging of HCC, higher Edmonson-Steiner classification, intrahepatic metastases, portal vein invasion, higher MRC2 and higher TGFβ1 were the poor prognostic factors. </plain></SENT>
<SENT sid="7" pm="."><plain>Furthermore, multivariate analysis revealed that intrahepatic metastases, higher MRC2 and higher TGFβ1 were the independent prognostic factors. </plain></SENT>
<SENT sid="8" pm="."><plain>TGFβ1 treatment up-regulated MRC2 expression, cell migration and invasion of Huh7 cells notably. </plain></SENT>
<SENT sid="9" pm="."><plain>In addition, knockdown of MRC2 repressed the effect of TGFβ1 on cell migration and invasion. </plain></SENT>
<SENT sid="10" pm="."><plain>These data suggest that MRC2 overexpression predicts poor prognosis of HCCs after liver resection and MRC2 potentially contributed to TGFβ1-driven up-regulation of cell migration and invasion in HCC. </plain></SENT>
</text></SecTag></p></abstract><SecTag type="KEYWORD"><kwd-group><kwd>MRC2</kwd><kwd>hepatocellular carcinoma</kwd><kwd>TGFβ1</kwd><kwd>prognosis</kwd></kwd-group></SecTag></article-meta></front><body><SecTag type="INTRO"><sec><title><text><SENT sid="11" pm="."><plain>1. </plain></SENT>
<SENT sid="12" pm="."><plain>Introduction </plain></SENT>
</text></title><p><text><SENT sid="13" pm="."><plain>Hepatocellular carcinoma (HCC) is one of the highly prevalent malignant diseases and is the third leading cause of cancer related death all through the world [1]. </plain></SENT>
<SENT sid="14" pm="."><plain>Incidences of the disease continue to increase year after year [2]. </plain></SENT>
<SENT sid="15" pm="."><plain>Because there are no typical clinical manifestations and high metastasis capacity at the early stage, most HCC patients cannot receive curative surgical treatments including radical liver resection and liver transplantation. </plain></SENT>
<SENT sid="16" pm="."><plain>Additionally, due to its high recurrence and metastasis characteristics, the prognosis of HCC after hepatic resections including curative one and palliative one is dismal. </plain></SENT>
<SENT sid="17" pm="."><plain>Therefore, there is an urgent need to figure out the underlying molecular mechanism of high metastasis capacity of HCC and explore the novel markers predicting HCC metastasis efficaciously in clinic. </plain></SENT>
</text></p><p><text><SENT sid="18" pm="."><plain>Cancer metastasis is a kind of tissue remodeling process in which normal tissue in the local organ and or distant organs is invaded and eventually completely replaced by cancer tissues [3]. </plain></SENT>
<SENT sid="19" pm="."><plain>The deposition and degradation of the extracellular matrix are the critical features of cancer metastasis. </plain></SENT>
<SENT sid="20" pm="."><plain>Among them, there are multiple functions of extracellular matrix degradation on tumor progression including: (1) providing tumor mass more space to spread; (2) liberating more latent growth factors from extracellular matrix and activating oncogenic cell signalings in neighboring tumor cells; (3) facilitating the formation of neovasculature within tumor mass; (4) abolishing the restrictions of tumor cell proliferation from extracellular matrix [4]. </plain></SENT>
<SENT sid="21" pm="."><plain>Thus, it is crucial to demonstrate the mechanism of extracellular matrix degradation. </plain></SENT>
</text></p><p><text><SENT sid="22" pm="."><plain>Transforming growth factor (TGFβ1) is a pleiotropic cytokine which contributes to wound healing, angiogenesis, fibrosis and cancer [5]. </plain></SENT>
<SENT sid="23" pm="."><plain>It was first identified in mammary epithelial development by Daniel and his colleagues in 1987 [6]. </plain></SENT>
<SENT sid="24" pm="."><plain>A growing body of evidences showed that TGFβ1 functions as either a tumor suppressor or a tumor promoter [7,8,9,10,11,12] via both SMAD (drosophila mothers against decapentaplegic protein)-dependent and SMAD-independent cascades. </plain></SENT>
<SENT sid="25" pm="."><plain>In fact, the multifunctional activities of TGFβ1 depends on the stage of carcinogenesis. </plain></SENT>
<SENT sid="26" pm="."><plain>In normal epithelia, it acts as tumor repressors through both inhibiting cell proliferation and inducing apoptosis, whereas accelerating progression of established cancers via activating various oncogenic cell signals and inducing EMT directly [11,13,14]. </plain></SENT>
<SENT sid="27" pm="."><plain>Generally, the tumor promoter function of TGFβ1 in the context of cancer progression results from two actions including losing its inhibitory effect on carcinogenesis and awaking its oncogenic function. </plain></SENT>
<SENT sid="28" pm="."><plain>Therefore, it is important to explore the key factors which play an important roles in the conversion of TGFβ1 function from a tumor suppressor to a tumor promoter. </plain></SENT>
</text></p><p><text><SENT sid="29" pm="."><plain>Mannose Receptor C Type 2 (MRC2), also known as uPARAP/Endo180, is a constitutively recycling endocytic receptor belonging to the mannose receptor family [15]. </plain></SENT>
<SENT sid="30" pm="."><plain>Through the endocytic function, MRC2 is found to bind and internalize both intact and degraded collagens and in turn take part in the turnover of collagens in both cytomembrane and extracellular matrix [16]. </plain></SENT>
<SENT sid="31" pm="."><plain>Recently, there have been accumulating reports showing that MRC2 is aberrantly up-regulated in a variety of cancers and closely involved in cancer metastasis including breast cancer [17,18], prostate cancer [19], head stroma, and neck cancer [20]. </plain></SENT>
<SENT sid="32" pm="."><plain>However, the expression of MRC2 and its role in HCC remain unclear. </plain></SENT>
<SENT sid="33" pm="?"><plain>In this study, we attempted to address the following questions: (1) Is MRC2 expression up-regulated aberrantly in HCC tissues compared to adjacent liver tissues? </plain></SENT>
<SENT sid="34" pm="?"><plain>(2) What is the relationship between MRC2 expression in HCC tissues and HCC prognosis after liver resection? </plain></SENT>
<SENT sid="35" pm="?"><plain>(3) What is the correlation between TGFβ1 and MRC2? </plain></SENT>
<SENT sid="36" pm="?"><plain>(4) Is MRC2 attributed to the oncogenic effect of TGFβ1 in HCC? </plain></SENT>
</text></p></sec></SecTag><SecTag type="RESULTS,DISCUSS"><sec><title><text><SENT sid="37" pm="."><plain>2. </plain></SENT>
<SENT sid="38" pm="."><plain>Results and Discussion </plain></SENT>
</text></title><sec><title><text><SENT sid="39" pm="."><plain>2.1. </plain></SENT>
<SENT sid="40" pm="."><plain>Mannose Receptor C Type 2 (MRC2) Was Over-Expressed in Hepatocellular Carcinoma (HCC) Tissues and Associated with Poor Prognosis after Liver Resection </plain></SENT>
</text></title><p><text><SENT sid="41" pm="."><plain>To observe MRC2 expression in HCC, immunohistochemistry (IHC) staining assays were carried out and it was found that MRC2 protein located in both cell membrane and cytoplasm, as shown in Figure 1a. </plain></SENT>
<SENT sid="42" pm="."><plain>By analyzing the IHC score using the Mann–Whitney U test, we found that MRC2 expression in HCC tissues was significantly higher than one in adjacent liver tissues (p &lt; 0.001; Figure 1c). </plain></SENT>
<SENT sid="43" pm="."><plain>We also examined MRC2 expression by western immunoblotting in 3 pairs of representative HCC tissues and adjacent liver tissues. </plain></SENT>
<SENT sid="44" pm="."><plain>As shown in Figure 1b, there was significantly more MRC2 expression in HCC tissues than in adjacent liver tissues. </plain></SENT>
<SENT sid="45" pm="."><plain>The relationship between MRC2 and the clinicopathological parameters of the 96 HCCs was statistically assessed and the results were listed in Table 1. </plain></SENT>
<SENT sid="46" pm="."><plain>The expression of MRC2 was significantly associated with intrahepatic metastases (r = 0.485, p = 0.005) and portal vein invasion (r = 0.214, p = 0.002). </plain></SENT>
<SENT sid="47" pm="."><plain>However, there was no significant correlation between MRC2 expression in HCC tissues and gender (r = −0.16, p = 0.062), age (r = 0.344, p = 0.121), HBV infection (r = 0.312, p = 0.075), liver cirrhosis (r = 0.12, p = 0.063), serumα-fetoprotein (AFP) level (r = 0.322, p = 0.130), tumor size (r = 0.271, p = 0.091), Edmonson–Steiner classification (r = 0.332, p = 0.130) and vasculature invasion (r = 0.070, p = 0.071). </plain></SENT>
</text></p><SecTag type="FIG"><fig id="ijms-15-15011-f001" position="float"><label>Figure 1</label><caption><p><text><SENT sid="48" pm="."><plain>(a) (I) The representative immunohistochemistry (IHC) staining of MRC2 in HCC tissues. </plain></SENT>
<SENT sid="49" pm="."><plain>MRC2 protein located in both cell membrane (black arrow) and cytoplasm (white arrow); (II) The representative IHC staining of MRC2 in adjacent liver tissues; (III) The negative staining of MRC2 in HCC tissues; (b) The western immunoblotting results of MRC2 in 3 pairs of representative HCC tissues (T) and adjacent liver tissues (N); (c) The IHC scores of MRC2 in HCC tissues were significantly higher than one in adjacent liver tissues (p &lt; 0.001); and (d) The comparison of Kaplan–Meier survival curves showed that patients with higher MRC2 expression in HCC tissues had worse prognosis after liver resection (HR = 3.071; 95% CI: 1.357, 6.951; p = 0.007). </plain></SENT>
</text></p></caption><graphic xlink:href="ijms-15-15011-g001"/></fig></SecTag><SecTag type="TABLE"><table-wrap id="ijms-15-15011-t001" position="float"><object-id pub-id-type="pii">ijms-15-15011-t001_Table 1</object-id><label>Table 1</label><caption><p><text><SENT sid="50" pm="."><plain>Correlation between the Clinicopathological Parameters and Mannose Receptor C Type 2 (MRC2) Expression in 96 HCCs. </plain></SENT>
</text></p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="2" align="center" valign="middle" rowspan="1"><text><SENT sid="51" pm="."><plain>Clinicopathological Parameters </plain></SENT>
</text></th><th align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="52" pm="."><plain>No. of Higher MRC2 Expression in HCC Tissues </plain></SENT>
</text></th><th align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="53" pm="."><plain>r-Value </plain></SENT>
</text></th><th align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="54" pm="."><plain>p-Value </plain></SENT>
</text></th></tr></thead><tbody><tr><td rowspan="2" align="center" valign="middle" colspan="1"><text><SENT sid="55" pm="."><plain>Gender </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="56" pm="."><plain>Female (n = 39) </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="57" pm="."><plain>28 </plain></SENT>
</text></td><td rowspan="2" align="center" valign="middle" colspan="1"><text><SENT sid="58" pm="."><plain>−0.16 </plain></SENT>
</text></td><td rowspan="2" align="center" valign="middle" colspan="1"><text><SENT sid="59" pm="."><plain>0.062 </plain></SENT>
</text></td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="60" pm="."><plain>Male (n = 57) </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="61" pm="."><plain>34 </plain></SENT>
</text></td></tr><tr style="border-top: solid thin"><td rowspan="2" align="center" valign="middle" colspan="1"><text><SENT sid="62" pm="."><plain>Age </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="63" pm="."><plain>&gt;50 (n = 49) </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="64" pm="."><plain>43 </plain></SENT>
</text></td><td rowspan="2" align="center" valign="middle" colspan="1"><text><SENT sid="65" pm="."><plain>0.344 </plain></SENT>
</text></td><td rowspan="2" align="center" valign="middle" colspan="1"><text><SENT sid="66" pm="."><plain>0.121 </plain></SENT>
</text></td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="67" pm="."><plain>&lt;50 (n = 47) </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="68" pm="."><plain>19 </plain></SENT>
</text></td></tr><tr style="border-top: solid thin"><td rowspan="2" align="center" valign="middle" colspan="1"><text><SENT sid="69" pm="."><plain>HBV Infection </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="70" pm="."><plain>Yes (n = 76) </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="71" pm="."><plain>59 </plain></SENT>
</text></td><td rowspan="2" align="center" valign="middle" colspan="1"><text><SENT sid="72" pm="."><plain>0.312 </plain></SENT>
</text></td><td rowspan="2" align="center" valign="middle" colspan="1"><text><SENT sid="73" pm="."><plain>0.075 </plain></SENT>
</text></td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="74" pm="."><plain>No (n = 20) </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="75" pm="."><plain>3 </plain></SENT>
</text></td></tr><tr style="border-top: solid thin"><td rowspan="2" align="center" valign="middle" colspan="1"><text><SENT sid="76" pm="."><plain>Liver Cirrhosis </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="77" pm="."><plain>Yes (n = 89) </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="78" pm="."><plain>61 </plain></SENT>
</text></td><td rowspan="2" align="center" valign="middle" colspan="1"><text><SENT sid="79" pm="."><plain>0.12 </plain></SENT>
</text></td><td rowspan="2" align="center" valign="middle" colspan="1"><text><SENT sid="80" pm="."><plain>0.063 </plain></SENT>
</text></td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="81" pm="."><plain>No (n = 7) </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="82" pm="."><plain>1 </plain></SENT>
</text></td></tr><tr style="border-top: solid thin"><td rowspan="2" align="center" valign="middle" colspan="1"><text><SENT sid="83" pm="."><plain>High Serum AFP Level </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="84" pm="."><plain>&gt;400 ng/mL </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="85" pm="."><plain>38 </plain></SENT>
</text></td><td rowspan="2" align="center" valign="middle" colspan="1"><text><SENT sid="86" pm="."><plain>0.322 </plain></SENT>
</text></td><td rowspan="2" align="center" valign="middle" colspan="1"><text><SENT sid="87" pm="."><plain>0.130 </plain></SENT>
</text></td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="88" pm="."><plain>&lt;400 ng/mL </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="89" pm="."><plain>24 </plain></SENT>
</text></td></tr><tr style="border-top: solid thin"><td rowspan="2" align="center" valign="middle" colspan="1"><text><SENT sid="90" pm="."><plain>Tumor Size </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="91" pm="."><plain>&gt;5 cm </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="92" pm="."><plain>40 </plain></SENT>
</text></td><td rowspan="2" align="center" valign="middle" colspan="1"><text><SENT sid="93" pm="."><plain>0.271 </plain></SENT>
</text></td><td rowspan="2" align="center" valign="middle" colspan="1"><text><SENT sid="94" pm="."><plain>0.091 </plain></SENT>
</text></td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="95" pm="."><plain>&lt;5 cm </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="96" pm="."><plain>22 </plain></SENT>
</text></td></tr><tr style="border-top: solid thin"><td rowspan="2" align="center" valign="middle" colspan="1"><text><SENT sid="97" pm="."><plain>Intrahepatic Metastases </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="98" pm="."><plain>Yes (n = 18) </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="99" pm="."><plain>16 </plain></SENT>
</text></td><td rowspan="2" align="center" valign="middle" colspan="1"><text><SENT sid="100" pm="."><plain>0.485 </plain></SENT>
</text></td><td rowspan="2" align="center" valign="middle" colspan="1"><text><SENT sid="101" pm="."><plain>0.005 </plain></SENT>
</text></td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="102" pm="."><plain>No (n = 78) </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="103" pm="."><plain>46 </plain></SENT>
</text></td></tr><tr style="border-top: solid thin"><td rowspan="2" align="center" valign="middle" colspan="1"><text><SENT sid="104" pm="."><plain>Portal Vein Invasion </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="105" pm="."><plain>Yes (n = 9) </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="106" pm="."><plain>9 </plain></SENT>
</text></td><td rowspan="2" align="center" valign="middle" colspan="1"><text><SENT sid="107" pm="."><plain>0.214 </plain></SENT>
</text></td><td rowspan="2" align="center" valign="middle" colspan="1"><text><SENT sid="108" pm="."><plain>0.002 </plain></SENT>
</text></td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="109" pm="."><plain>No (n = 87) </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="110" pm="."><plain>53 </plain></SENT>
</text></td></tr><tr style="border-top: solid thin"><td rowspan="2" align="center" valign="middle" colspan="1"><text><SENT sid="111" pm="."><plain>Portal Vein Invasion </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="112" pm="."><plain>Yes (n = 9) </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="113" pm="."><plain>9 </plain></SENT>
</text></td><td rowspan="2" align="center" valign="middle" colspan="1"><text><SENT sid="114" pm="."><plain>0.214 </plain></SENT>
</text></td><td rowspan="2" align="center" valign="middle" colspan="1"><text><SENT sid="115" pm="."><plain>0.002 </plain></SENT>
</text></td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="116" pm="."><plain>No (n = 87) </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="117" pm="."><plain>53 </plain></SENT>
</text></td></tr><tr style="border-top: solid thin"><td rowspan="2" align="center" valign="middle" colspan="1"><text><SENT sid="118" pm="."><plain>Edmonson–Steiner Classification </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="119" pm="."><plain>I and II (n = 34) </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="120" pm="."><plain>24 </plain></SENT>
</text></td><td rowspan="2" align="center" valign="middle" colspan="1"><text><SENT sid="121" pm="."><plain>0.332 </plain></SENT>
</text></td><td rowspan="2" align="center" valign="middle" colspan="1"><text><SENT sid="122" pm="."><plain>0.130 </plain></SENT>
</text></td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="123" pm="."><plain>III and IV (n = 62) </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="124" pm="."><plain>38 </plain></SENT>
</text></td></tr><tr style="border-top: solid thin"><td rowspan="2" align="center" valign="middle" colspan="1"><text><SENT sid="125" pm="."><plain>Advanced TNM Stage </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="126" pm="."><plain>I and II (n = 52) </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="127" pm="."><plain>26 </plain></SENT>
</text></td><td rowspan="2" align="center" valign="middle" colspan="1"><text><SENT sid="128" pm="."><plain>0.151 </plain></SENT>
</text></td><td rowspan="2" align="center" valign="middle" colspan="1"><text><SENT sid="129" pm="."><plain>0.032 </plain></SENT>
</text></td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="130" pm="."><plain>III and IV (n = 44) </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="131" pm="."><plain>36 </plain></SENT>
</text></td></tr><tr style="border-top: solid thin"><td rowspan="2" align="center" valign="middle" colspan="1"><text><SENT sid="132" pm="."><plain>Vasculature Invasion * </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="133" pm="."><plain>Yes (n = 12) </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="134" pm="."><plain>7 </plain></SENT>
</text></td><td rowspan="2" align="center" valign="middle" colspan="1"><text><SENT sid="135" pm="."><plain>0.070 </plain></SENT>
</text></td><td rowspan="2" align="center" valign="middle" colspan="1"><text><SENT sid="136" pm="."><plain>0.071 </plain></SENT>
</text></td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="137" pm="."><plain>No (n = 84) </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="138" pm="."><plain>55 </plain></SENT>
</text></td></tr></tbody></table><table-wrap-foot><fn><p><text><SENT sid="139" pm="."><plain>* Vasculature invasion means microscopic vein invasion; AFP: serumα-fetoprotein; TNM: TNM Classification for Hepatocellular Carcinoma. </plain></SENT>
</text></p></fn></table-wrap-foot></table-wrap></SecTag><p><text><SENT sid="140" pm="."><plain>We obtained the follow-up information from 72 of 96 HCC cases (75%). </plain></SENT>
<SENT sid="141" pm="."><plain>The median time of follow-up was 18 months. </plain></SENT>
<SENT sid="142" pm="."><plain>We compared the Kaplan-Meier survival curves between the high MRC2 group, in which HCC tissues had more MRC2 expression than adjacent liver tissues, and in the low MRC2 group and found that the high MRC2 group had clearly worse prognosis after liver resection than the low MRC2 group (HR = 3.071; 95% CI: 1.357, 6.951; p = 0.007; Figure 1d), which pointed out that MRC2 over-expression in HCC tissues was an important factor associated with poor outcome after liver resection. </plain></SENT>
<SENT sid="143" pm="."><plain>After univariate analysis, it was found that advanced TNM staging, higher Edmonson–Steiner classification, intrahepatic metastases, portal vein invasion, higher MRC2 and higher TGFβ1 were the poor prognostic factors. </plain></SENT>
<SENT sid="144" pm="."><plain>Furthermore, multivariate analysis revealed that intrahepatic metastases, higher MRC2 and higher TGFβ1 were the independent prognostic factors for HCC patients after liver resection (as shown in Table 2). </plain></SENT>
</text></p><SecTag type="TABLE"><table-wrap id="ijms-15-15011-t002" position="float"><object-id pub-id-type="pii">ijms-15-15011-t002_Table 2</object-id><label>Table 2</label><caption><p><text><SENT sid="145" pm="."><plain>Cox proportional-hazard regression analysis of the relationship between clinicopathologic parameters and overall survival rate of HCC Patients after liver resection. </plain></SENT>
</text></p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" align="center" valign="middle" colspan="1"><text><SENT sid="146" pm="."><plain>Clinicopathologic Parameters </plain></SENT>
</text></th><th colspan="2" align="center" valign="middle" rowspan="1"><text><SENT sid="147" pm="."><plain>Unvariate Analysis </plain></SENT>
</text></th><th colspan="2" align="center" valign="middle" rowspan="1"><text><SENT sid="148" pm="."><plain>Multivariate Analysis </plain></SENT>
</text></th></tr><tr style="border-top: solid thin"><th align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="149" pm="."><plain>RR (95% CI) </plain></SENT>
</text></th><th align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="150" pm="."><plain>p-Value </plain></SENT>
</text></th><th align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="151" pm="."><plain>RR (95% CI) </plain></SENT>
</text></th><th align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="152" pm="."><plain>p-Value </plain></SENT>
</text></th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="153" pm="."><plain>Intrahepatic Metastases </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="154" pm="."><plain>3.120 (2.132–6.324) </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="155" pm="."><plain>0.001 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="156" pm="."><plain>2.975 (1.587–4.525) </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="157" pm="."><plain>0.003 </plain></SENT>
</text></td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="158" pm="."><plain>Higher MRC2 Expression in HCC Tissue </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="159" pm="."><plain>1.856 (1.323–2.241) </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="160" pm="."><plain>0.012 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="161" pm="."><plain>2.035 (1.785–2.995) </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="162" pm="."><plain>0.015 </plain></SENT>
</text></td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="163" pm="."><plain>Higher TGFβ1 Expression in HCC Tissue </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="164" pm="."><plain>1.697 (1.022–1.975) </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="165" pm="."><plain>0.030 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="166" pm="."><plain>1.882 (1.211–2.214) </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="167" pm="."><plain>0.022 </plain></SENT>
</text></td></tr></tbody></table></table-wrap></SecTag></sec><sec><title><text><SENT sid="168" pm="."><plain>2.2. </plain></SENT>
<SENT sid="169" pm="."><plain>Transforming Growth Factor (TGFβ1) Was Up-Regulated in HCC Tissues and Associated with MRC2 Positively </plain></SENT>
</text></title><p><text><SENT sid="170" pm="."><plain>To determine the relationship between TGFβ1 and MRC2 in HCC tissues, we also observed TGFβ1 expression in both HCC tissues and adjacent liver tissues by IHC staining. </plain></SENT>
<SENT sid="171" pm="."><plain>As shown in Figure 2a, the majority of positive TGFβ1 staining cells showed diffused cytoplasmic staining. </plain></SENT>
<SENT sid="172" pm="."><plain>After analyzing the IHC scores by the Mann–Whitney test, we found that the expression of TGFβ1 in HCC tissues was apparently more than one in adjacent liver tissues (p &lt; 0.001; Figure 2c). </plain></SENT>
<SENT sid="173" pm="."><plain>Additionally, expression of TGF β1 in the representative HCC tissues was found apparently more than that in the matching adjacent liver tissues (shown in Figure 2b). </plain></SENT>
<SENT sid="174" pm="."><plain>The Spearmen rank test also verified that there was a significantly positive correlation between TGFβ1 and MRC2 expression in HCC tissues (r = 0.347, p &lt; 0.001; Figure 2d), which initially indicated that TGFβ1 could be involved in aberrant over-expression of MRC2 in HCC. </plain></SENT>
</text></p></sec><sec><title><text><SENT sid="175" pm="."><plain>2.3. </plain></SENT>
<SENT sid="176" pm="."><plain>TGFβ1 Treatment Up-Regulated MRC2 Expression and Enhanced Cell Mobility and Invasion of HCC Cells </plain></SENT>
</text></title><p><text><SENT sid="177" pm="."><plain>To examine further whether TGFβ1 take part in aberrant MRC2 over-expression in HCC, we treated Huh7 cells with recombinant human TGFβ1 protein in vitro. </plain></SENT>
<SENT sid="178" pm="."><plain>It was found that MRC2 expression of Huh7 cells was increased at the level of both mRNA and protein 48 h after TGFβ1 treatment at the concentration of 10 ng/mL (Figure 3a). </plain></SENT>
<SENT sid="179" pm="."><plain>The scratch wound healing migration assay showed that the migration rate of Huh7 cells stimulated by TGFβ1 (TGFβ1 group) was obviously higher than that of control Huh7 cells (Control group) at 24 and 48 h after scratching (p = 0.005 and p = 0.002, respectively; Figure 3b). </plain></SENT>
<SENT sid="180" pm="."><plain>In the invasion assay, there were 94 ± 6 Huh7 cells per field crossing the Matrigel gel and chamber filter in TGFβ1 group, whereas 65 ± 4 Huh7 cells per field in Control group (p = 0.002; Figure 3c). </plain></SENT>
<SENT sid="181" pm="."><plain>To further verify the regulatory function of TGFβ1 on MRC2 expression in HCC cells, we treated Hep3B cells with TGF β1. </plain></SENT>
<SENT sid="182" pm="."><plain>Similarly, MRC2 expression was found to be increased apparently by both qRT-PCR and western immunoblotting, as shown in Figure 3d. </plain></SENT>
<SENT sid="183" pm="."><plain>The migration and invasion capacities of Hep3B cells were also promoted by TGFβ1 treatment (Figure 3e,f). </plain></SENT>
<SENT sid="184" pm="."><plain>These data strongly supported that TGFβ1 promoted tumor cell mobility and invasion and meanwhile induced up-regulation of MRC2 in HCC cells. </plain></SENT>
</text></p><SecTag type="FIG"><fig id="ijms-15-15011-f002" position="float"><label>Figure 2</label><caption><p><text><SENT sid="185" pm="."><plain>(a) (I) The representative IHC staining of Transforming growth factor (TGFβ1) in HCC tissues; (II) The representative IHC staining of TGFβ1 in adjacent liver tissues; (III) The negative staining of TGFβ1 in HCC tissues; (b) The western immunoblotting results of TGFβ1 in 3 pairs of representative HCC tissues (T) and adjacent liver tissues (N); (c) The IHC scores of TGFβ1 in HCC tissues were significantly higher than one in adjacent liver tissues (p &lt; 0.001); (d) The Spearmen rank test showed that there was positive correlation between TGFβ1 and MRC2 expression in HCC tissues (r = 0.347; p &lt; 0.001). </plain></SENT>
</text></p></caption><graphic xlink:href="ijms-15-15011-g002"/></fig></SecTag><SecTag type="FIG"><fig id="ijms-15-15011-f003" position="float"><label>Figure 3</label><caption><p><text><SENT sid="186" pm="."><plain>(a) As assessed by both western immunoblotting and qRT-PCR assays, TGFβ1 treatment leaded to up-regulation of MRC2 in Huh7 cells significantly; (b) TGFβ1 treatment promoted migration of Huh7 cells apparently; (c) Invasion capacity of Huh7 cells was significantly enhanced by TGFβ1 treatment (p = 0.002); (d) Both qRT-PCR and western immunoblotting revealed that TGFβ1 treatment resulted in a significant increase of MRC2 expression in Hep3B cells; (e) The migration ability of Hep3B cells was increased by TGFβ1 treatment obviously; (f) Millicell invasion chamber assay showed that TGFβ1 treatment up-regulated invasion ability of Hep3B cells clearly. </plain></SENT>
</text></p></caption><graphic xlink:href="ijms-15-15011-g003"/></fig></SecTag></sec><sec><title><text><SENT sid="187" pm="."><plain>2.4. </plain></SENT>
<SENT sid="188" pm="."><plain>Knockdown of MRC2 Abolished the Effect of TGFβ1 on Cell Mobility and Invasion </plain></SENT>
</text></title><p><text><SENT sid="189" pm="."><plain>To investigate whether MRC2 plays an important role in the oncogenic function of TGFβ1, we transfected MRC2 siRNA into Huh7 cells one day before TGFβ1 treatment in order to repress MRC2 up-regulation induced by TGFβ1. </plain></SENT>
<SENT sid="190" pm="."><plain>The qRT-PCR and western immunoblotting assays both confirmed that there was not a significant increase in MRC2 expression of Huh7 cells after TGFβ1 treatment (Figure 4A). </plain></SENT>
<SENT sid="191" pm="."><plain>As shown in Figure 4B, after suppression of MRC2 up-regulation in Huh7 cells, there was no significant difference on cell migration rate between TGFβ1 group and Control group found at 24 and 48 h after scratching (p = 0.086 and p = 0.815, respectively). </plain></SENT>
<SENT sid="192" pm="."><plain>Consistently, the number of cell crossing both the Matrigel gel and chamber filter in TGFβ1 group was similar with that in Control group, as assessed by the invasion assay (p = 0.449; Figure 4C). </plain></SENT>
<SENT sid="193" pm="."><plain>Hence, it was demonstrated by these data that TGFβ1 couldn’t promote mobility and invasion ability of Huh7 cells without MRC2. </plain></SENT>
</text></p><SecTag type="FIG"><fig id="ijms-15-15011-f004" position="float"><label>Figure 4</label><caption><p><text><SENT sid="194" pm="."><plain>(a) As assessed by both western immunoblotting and qRT-PCR assays, TGFβ1 treatment leaded to up-regulation of MRC2 in Huh7 cells significantly; (b) TGFβ1 treatment promoted migration of Huh7 cells apparently; and (c) Invasion capacity of Huh7 cells was significantly enhanced by TGFβ1 treatment (p = 0.001). </plain></SENT>
</text></p></caption><graphic xlink:href="ijms-15-15011-g004"/></fig></SecTag></sec><sec><title><text><SENT sid="195" pm="."><plain>2.5. </plain></SENT>
<SENT sid="196" pm="."><plain>TGFβ1/Smad3 Pathway Regulated MRC2 Expression in HCC Directly </plain></SENT>
</text></title><p><text><SENT sid="197" pm="."><plain>To reveal the role of TGFβ1 on the transcriptional regulation of MRC2 in HCC, we identified several potential Smad binding sites in the gene promoter of MRC2 using MatInspector professional version 7.2 (shown in Figure 5a). </plain></SENT>
<SENT sid="198" pm="."><plain>The chromatin immunoprecipitation (ChIP) assay was carried out to test the direct interaction between Smad and the MRC2 promoter in Huh7 cells treated with TGFβ1 and confirmed that Smad protein was bound with the promoter of MRC2 gene in the nucleus of HCC cells, as shown in Figure 5b. </plain></SENT>
<SENT sid="199" pm="."><plain>Hence, the −955/−401 bp MRC2 promoter fragment was initially identified to contain the Smad binding sites and the −955/−1 bp fragment reconstituted into the luciferase reporter vector, pGL3-basic. </plain></SENT>
<SENT sid="200" pm="."><plain>To address whether Smad3 contributes to the regulatory effect of TGFβ1 on MRC2 expression, we treated Huh7 cells with SIS3, a kind of Smad3 inhibitor. </plain></SENT>
<SENT sid="201" pm="."><plain>As shown in Figure 5c, SIS3 treatment resulted in an apparent decrease in MRC2 promoter activity in the presence of TGFβ1, as assessed by luciferase report assay. </plain></SENT>
<SENT sid="202" pm="."><plain>Thus, these data strongly supported that TGFβ1/Smad3 signaling up-regulated the expression of MRC2 in HCC cells via mediating positively its transcription directly. </plain></SENT>
</text></p><SecTag type="FIG"><fig id="ijms-15-15011-f005" position="float"><label>Figure 5</label><caption><p><text><SENT sid="203" pm="."><plain>(a) Schematic diagram of the potential Smad binding sites in the promoter of MRC2 which shows there are six neighboring potential Smad binding sites in the −955/−401 bp MRC2 promoter fragment; (b) With the help of ChIP assay, we obtained the DNA fragments bound with Smad protein in the nucleus of Huh7 cells. </plain></SENT>
<SENT sid="204" pm="."><plain>As assessed by PCR assay, TGFβ1 treatment increased significantly the occupancy of Smad protein in the MRC2 promoter; (c) The luciferase reporter assay showed that TGFβ1 treatment leaded to more MRC2 luciferase activity in Huh7 cells, which was abolished by the Smad3 inhibitor SIS3. </plain></SENT>
<SENT sid="205" pm="."><plain>These data strongly demonstrated that Smad3 was involved closely in the regulatory effect of TGFβ1 on MRC2 expression. </plain></SENT>
</text></p></caption><graphic xlink:href="ijms-15-15011-g005"/></fig></SecTag></sec></sec></SecTag><sec><title><text><SENT sid="206" pm="."><plain>3. </plain></SENT>
<SENT sid="207" pm="."><plain>Experimental Section </plain></SENT>
</text></title><sec><title><text><SENT sid="208" pm="."><plain>3.1. </plain></SENT>
<SENT sid="209" pm="."><plain>Patients and Specimens </plain></SENT>
</text></title><p><text><SENT sid="210" pm="."><plain>There were a total of 96 HCC patients recruited in this investigation which underwent liver resection in our hospital from 2009 to 2010. </plain></SENT>
<SENT sid="211" pm="."><plain>HCC tissues and adjacent liver tissues (&gt;2 cm distance to the resection margin) were obtained and kept in paraformaldehyde immediately. </plain></SENT>
<SENT sid="212" pm="."><plain>The diagnosis of all patients was confirmed by pathologists. </plain></SENT>
<SENT sid="213" pm="."><plain>Not all patients did received chemotherapy or embolization therapy before surgery. </plain></SENT>
<SENT sid="214" pm="."><plain>Demographic, clinical and histopathological information were collected from the medical records and shown in Table 1. </plain></SENT>
<SENT sid="215" pm="."><plain>The follow-up was carried out by our group to analyze postsurgical over-all survival of HCCs. </plain></SENT>
<SENT sid="216" pm="."><plain>Written informed consent was obtained from all patients recruited in this study. </plain></SENT>
<SENT sid="217" pm="."><plain>The ethics committee of the First Affiliated Hospital of Xi’an Jiaotong University approved all protocols according to the Helsinki Declaration of 2013 (No.20080301, 6 May 2008). </plain></SENT>
</text></p></sec><sec><title><text><SENT sid="218" pm="."><plain>3.2. </plain></SENT>
<SENT sid="219" pm="."><plain>Immunohistochemistry Staining </plain></SENT>
</text></title><p><text><SENT sid="220" pm="."><plain>Paraffin-embedded tissue sections were subjected to immunohistochemical analysis as described previously [21]. </plain></SENT>
<SENT sid="221" pm="."><plain>The primary rabbit anti-MRC2 antibody (Catalog No.: ab70132) and primary rabbit anti-TGFβ1 antibody (Catalog No.: ab92486) were both obtained from Abcam (Cambridge, MA, USA). </plain></SENT>
<SENT sid="222" pm="."><plain>The slides were dewaxed and dehydrated. </plain></SENT>
<SENT sid="223" pm="."><plain>After rehydration, endogenous peroxidase activity was blocked for 30 min using a methanol solution containing 0.3% hydrogen peroxide. </plain></SENT>
<SENT sid="224" pm="."><plain>After antigen retrieval in citrate buffer, we blocked all slides at 4 °C overnight with 2% BSA. </plain></SENT>
<SENT sid="225" pm="."><plain>The slides were incubated respectively with the primary antibodies targeting MRC2 and TGFβ1 overnight at 4 °C. </plain></SENT>
<SENT sid="226" pm="."><plain>Then the slides were washing with PBS three times and incubated with the biotinylated secondary antibody which was purchased from Zhongshan Goldenbridge Biotechnology Limited Company (Beijing, China) according to the manufacturer’s instruction. </plain></SENT>
<SENT sid="227" pm="."><plain>We stained the slides by the avidin–biotin–peroxidase complex (SABC) method. </plain></SENT>
<SENT sid="228" pm="."><plain>The slides were visualized with diaminobenzidine and counterstained with hematoxylin. </plain></SENT>
<SENT sid="229" pm="."><plain>Finally, tissues were dehydrated in alcohol and xylene. </plain></SENT>
</text></p><p><text><SENT sid="230" pm="."><plain>Two experienced pathologists observed all slides independently to assess the Edmonson classification clinical TNM grading, maximum tumor diameter and the results of IHC assay. </plain></SENT>
<SENT sid="231" pm="."><plain>The results of IHC staining were evaluated by the staining intensity and the percentage of specifically positive staining tumor cells. </plain></SENT>
<SENT sid="232" pm="."><plain>Staining intensity was classified into four grades: 0, none; 1, weak; 2, moderate; 3, strong. </plain></SENT>
<SENT sid="233" pm="."><plain>The percentage of specifically positive staining tumor cells was given with the following grades: 0 (&lt;5%), 1 (6%–25%), 2 (26%–50%), 3 (51%–75%), and 4 (&gt;75%). </plain></SENT>
<SENT sid="234" pm="."><plain>The IHC staining score was expressed by multiplying the staining intensity and the percentage of specifically positive staining tumor cells. </plain></SENT>
<SENT sid="235" pm="."><plain>The IHC score of &gt;1 was considered as positive staining. </plain></SENT>
<SENT sid="236" pm="."><plain>Each slide was observed for 10 independent high magnification field (×400) to get the mean staining score. </plain></SENT>
<SENT sid="237" pm="."><plain>The representative figures of each score were shown in Figure 6. </plain></SENT>
</text></p><SecTag type="FIG"><fig id="ijms-15-15011-f006" position="float"><label>Figure 6</label><caption><p><text><SENT sid="238" pm="."><plain>(a) The representative MRC2 staining of HCC tissue with 1 score; (b) the representative MRC2 staining of HCC tissue with 6 score; (c) the representative MRC2 staining of HCC tissue with 12 score; (d) the representative MRC2 staining of adjacent liver tissue with 1 score; (e) the representative MRC2 staining of adjacent liver tissue with 6 score. </plain></SENT>
</text></p></caption><graphic xlink:href="ijms-15-15011-g006"/></fig></SecTag></sec><sec><title><text><SENT sid="239" pm="."><plain>3.3. </plain></SENT>
<SENT sid="240" pm="."><plain>Cell Culture and TGFβ1 Treatment </plain></SENT>
</text></title><p><text><SENT sid="241" pm="."><plain>Huh7 cell line was a kind gift from Kefeng Dou (Department of Hepatobiliary Surgery, Xijing Hospital, Fourth Military Medical University, Xi’an, China) and cultured with DMEM medium with 10% FBS at 37 °C in a humidified atmosphere of 95% air and 5% CO2. </plain></SENT>
<SENT sid="242" pm="."><plain>For TGFβ1 treatment, Huh7 cells were cultured with 1% FBS for 24 h and stimulated with 10 ng/mL of TGFβ1 for 48 h. </plain></SENT>
</text></p></sec><sec><title><text><SENT sid="243" pm="."><plain>3.4. </plain></SENT>
<SENT sid="244" pm="."><plain>RNAi Transfections </plain></SENT>
</text></title><p><text><SENT sid="245" pm="."><plain>We purchased the siRNAs against MRC2 (Catalog No.: sc-62276) and the scrambled siRNAs (Catalog No.: sc-37007) from Santa Cruz Biotechnology (Santa Cruz, CA, USA). </plain></SENT>
<SENT sid="246" pm="."><plain>Huh7 cells were plated in six-well plates at the concentration of 0.2 × 106 per well and cultured overnight. </plain></SENT>
<SENT sid="247" pm="."><plain>Then Huh7 cells in each well were transfected with 100 nM siRNAs using Lipofectamine RNAi MAX Reagent (Invitrogen, CA, USA) according to the manufacture’s recommendations. </plain></SENT>
<SENT sid="248" pm="."><plain>The cells were used for further experiments at 48 h after transfection. </plain></SENT>
</text></p></sec><sec><title><text><SENT sid="249" pm="."><plain>3.5. </plain></SENT>
<SENT sid="250" pm="."><plain>Western Immunoblotting </plain></SENT>
</text></title><p><text><SENT sid="251" pm="."><plain>Western immunoblotting assay was carried out as described previously [22]. </plain></SENT>
<SENT sid="252" pm="."><plain>Briefly speaking, 30 mg denatured protein samples were separated by polyacrylamide gel electrophoresis (PAGE) and then transferred into PVDF membrane. </plain></SENT>
<SENT sid="253" pm="."><plain>After blocked with 10% BSA in tris-buffered saline buffer (TBS) for 4 h at room temperature, the blots in PVDF membrane were incubated overnight with the primary antibodies respectively at 4 °C. </plain></SENT>
<SENT sid="254" pm="."><plain>After washed 3 times by tris-buffered saline buffer with tween 20 (TBST), the protein blots were labeled with the relevant secondary antibodies conjugated with Horseradish Peroxidase (HRP), and signals were visualized using the HyGLO HRP detection kit from Denville (Metuchen, NJ, USA). β-Actin was measured to control for equal loading. </plain></SENT>
</text></p></sec><sec><title><text><SENT sid="255" pm="."><plain>3.6. </plain></SENT>
<SENT sid="256" pm="."><plain>Quantitative Reverse-Transcription-Polymerase Chain Reaction (RT-PCR) </plain></SENT>
</text></title><p><text><SENT sid="257" pm="."><plain>Relative RT-PCR was conducted by TaqMan gene expression master mix from Applied Biosystems (Carlsbad, CA, USA). </plain></SENT>
<SENT sid="258" pm="."><plain>Briefly, total RNA was isolated from Huh7 cells using the RNeasy kit from Qiagen (Valencia, CA, USA). </plain></SENT>
<SENT sid="259" pm="."><plain>Reverse transcription was performed to synthesize cDNA by the High Capacity cDNA Reverse Transcription Kit from Applied Biosystems (Carlsbad, CA, USA). </plain></SENT>
<SENT sid="260" pm="."><plain>The TaqMan assays was performed in an ABI 7300 system using the following profile: 95 °C for 10 min followed by 40 cycles of 15 s at 95 °C and 60 s at 60 °C. </plain></SENT>
<SENT sid="261" pm="."><plain>MRC2 mRNA levels were normalized to 18 s rRNA mRNA levels in the same samples. </plain></SENT>
<SENT sid="262" pm="."><plain>The TaqMan probes for MRC2 (Hs00195862_m1) and 18s rRNA (Hs99999901_s1) were both from Applied Biosystems. </plain></SENT>
</text></p></sec><sec><title><text><SENT sid="263" pm="."><plain>3.7. </plain></SENT>
<SENT sid="264" pm="."><plain>Scratch Wound Healing Migration Assay </plain></SENT>
</text></title><p><text><SENT sid="265" pm="."><plain>Huh7 cells were plated into 6-well plates and cultured to more than 90% confluency. </plain></SENT>
<SENT sid="266" pm="."><plain>Scratch wound were made by a 1000-μL-pipette tip. </plain></SENT>
<SENT sid="267" pm="."><plain>Images of wounds were taken with a phase-contrast microscope at 0, 24 and 48 h. </plain></SENT>
<SENT sid="268" pm="."><plain>Cell migration was quantitated by measuring the width of the scratch wounds. </plain></SENT>
<SENT sid="269" pm="."><plain>Each experiment was repeated three times. </plain></SENT>
</text></p></sec><sec><title><text><SENT sid="270" pm="."><plain>3.8. </plain></SENT>
<SENT sid="271" pm="."><plain>Invasion Assay </plain></SENT>
</text></title><p><text><SENT sid="272" pm="."><plain>Invasion assay was performed using Millicell invasion chambers (8 mm pore size) from Millipore Corp (Billerica, MA, USA). </plain></SENT>
<SENT sid="273" pm="."><plain>Huh7 cells was grown in serum-free medium overnight and then plated into the upper chamber pre-coated with basement membrane Matrigel. </plain></SENT>
<SENT sid="274" pm="."><plain>The Huh7 cells were cultured in the upper chamber with serum-free medium and meanwhile the bottom chamber was filled with medium with 20% FBS. </plain></SENT>
<SENT sid="275" pm="."><plain>These cells were cultured at the normal condition. </plain></SENT>
<SENT sid="276" pm="."><plain>After 24 h, Huh7 cells remaining in the top surface of Matrigel membrane were swabbed carefully and the membrane was fixed with paraformaldehyde for 10 min. </plain></SENT>
<SENT sid="277" pm="."><plain>Huh7 cells in the membrane was stained by crystal violet solution and observed under microscope. </plain></SENT>
<SENT sid="278" pm="."><plain>Five fields were selected randomly to get the mean cell number in each membrane. </plain></SENT>
<SENT sid="279" pm="."><plain>Each exanimation was repeated six times. </plain></SENT>
</text></p></sec><sec><title><text><SENT sid="280" pm="."><plain>3.9. </plain></SENT>
<SENT sid="281" pm="."><plain>Chromatin Immunoprecipitation (ChIP) Assay </plain></SENT>
</text></title><p><text><SENT sid="282" pm="."><plain>The ChIP assay was performed as described in the previous study [11]. </plain></SENT>
<SENT sid="283" pm="."><plain>The primers used to detect the MRC2 promoter are designed as following: (forward: 5'-GTCTCAGTCCTGCCCTATGC-3'; reverse: 5'-CGAACTGGGGAGTCAGGATG-3'). </plain></SENT>
<SENT sid="284" pm="."><plain>The PCR products were separated by electrophoresis, visualized on a 2% agarose gel and compared by the densitometry. </plain></SENT>
<SENT sid="285" pm="."><plain>Each exanimation was repeated six times. </plain></SENT>
</text></p></sec><sec><title><text><SENT sid="286" pm="."><plain>3.10. </plain></SENT>
<SENT sid="287" pm="."><plain>Statistical Analysis </plain></SENT>
</text></title><p><text><SENT sid="288" pm="."><plain>Differences in MRC2 protein expression in HCC tissues compared to adjacent liver tissues were compared by the Mann–Whitney U test. </plain></SENT>
<SENT sid="289" pm="."><plain>The relationship between MRC2, TGFβ1 and clinical characteristics of HCCs was assessed using Spearman rank test respectively. </plain></SENT>
<SENT sid="290" pm="."><plain>Differences between the Kaplan–Meier curves of HCCs with high and low MRC2 expression in HCC tissues in comparison with adjacent liver tissues were evaluated by the log rank test. </plain></SENT>
<SENT sid="291" pm="."><plain>Statistical significance was accepted at p &lt; 0.05. </plain></SENT>
<SENT sid="292" pm="."><plain>Multivariate analysis was performed using SPSS V17.0 software (SPSS Inc., Chicago, IL, USA) and the PRISM 5 software (GraphPad, La Jolla, CA, USA) was used for other statistical analyses. </plain></SENT>
</text></p></sec></sec><SecTag type="CONCL"><sec><title><text><SENT sid="293" pm="."><plain>4. </plain></SENT>
<SENT sid="294" pm="."><plain>Conclusions </plain></SENT>
</text></title><p><text><SENT sid="295" pm="."><plain>HCC is one of the most frequently occurring tumors worldwide in the last decade. </plain></SENT>
<SENT sid="296" pm="."><plain>The treatment options with curative intent include radical liver resection, local ablation and liver transplantation at the early stage. </plain></SENT>
<SENT sid="297" pm="."><plain>Unfortunately, most HCC patients present at the advanced stage, which precludes the application of these curative treatments. </plain></SENT>
<SENT sid="298" pm="."><plain>As the effect of chemotherapy with conventional cytotoxic agents is unsatisfactory, therapy options for patients with advanced HCC are extremely limited. </plain></SENT>
<SENT sid="299" pm="."><plain>Tumor metastasis is the key death cause of HCC patients at the advanced stage and thus it is urgent to figure out the molecular mechanism of HCC metastasis and identify the novel therapy targets to prevent HCC metastasis. </plain></SENT>
</text></p><p><text><SENT sid="300" pm="."><plain>MRC2 is a 180-kDa type 1 transmembrane receptor that binds extracellular and intracellular collagens and internalizes them via clathrin-coated pits into early endosomes for lysosomal degradation [23]. </plain></SENT>
<SENT sid="301" pm="."><plain>There have been accumulating studies reported that MRC2 expression is increased aberrantly in a variety of cancers and associated with poor prognosis. </plain></SENT>
<SENT sid="302" pm="."><plain>Sulek et al. detected MRC2 expression in 112 human squamous cell carcinomas and 19 normal or tumor-adjacent head and neck tissue samples and found that expression of MCR2 was increased in tumor stroma compared with tumor-adjacent connective tissue and related positively with poor differentiation [20]. </plain></SENT>
<SENT sid="303" pm="."><plain>After analyzing 169 prostate tissue sections including benign prostatic hyperplasia and prostate cancer by immunofluorescence assay, Kogianni et al. found that MRC2 expression was clearly increased in both stromal tissues and epithelial tissues of prostate cancer compared to benign prostatic hyperplasia [19]. </plain></SENT>
<SENT sid="304" pm="."><plain>In glioblastoma multiforme, it was found that MRC2 was over-expressed in tumor tissues and attributed to mediating tumor cells invasion via collagen-containing matrices [24]. </plain></SENT>
<SENT sid="305" pm="."><plain>In this study, we reported for the first time that MRC2 expression was significantly higher in HCC tissues than that in adjacent liver tissues and associated with intrahepatic metastases and portal vein invasion. </plain></SENT>
<SENT sid="306" pm="."><plain>After comparing the Kaplan–Meier curves, we found that higher MRC2 expression in HCC tissues predicted worse outcome after liver resection. </plain></SENT>
<SENT sid="307" pm="."><plain>It was consistent with the results from the Palmieri group [17], reporting that MRC2 was an accuracy prognostic marker for breast cancer metastases. </plain></SENT>
<SENT sid="308" pm="."><plain>To determine the mechanism of over-expression of MRC2 in HCC, we measured TGFβ1 protein expression in the same HCC samples by IHC and found that there was positive correlation between MRC2 and TGFβ1 expression. </plain></SENT>
<SENT sid="309" pm="."><plain>TGFβ1 treatment leaded to up-regulation of MRC2 apparently in vitro, as well. </plain></SENT>
<SENT sid="310" pm="."><plain>Moreover, we found 6 potential Smad protein binding sites in the promoter of MRC2 gene and verified the direct interaction between Smad protein and the MRC2 promoter in HCC cells by ChIP assay. </plain></SENT>
<SENT sid="311" pm="."><plain>The inhibitor of Smad3 SIS3 inhibited the effect of TGFβ1 treatment on controlling MRC2 transcription in HCC cells dramatically. </plain></SENT>
<SENT sid="312" pm="."><plain>These indicated eventually that MRC2 over-expression could result from hyperactivation of TGFβ1/Smad3 signaling in HCC. </plain></SENT>
<SENT sid="313" pm="."><plain>Therefore, it was demonstrated that TGFβ1 regulated MRC2 expression in HCC, which is consistent with the findings in prostate cancer [25] and glioblastoma multiforme [24]. </plain></SENT>
</text></p><p><text><SENT sid="314" pm="."><plain>As known to all, TGFβ1 acts as both promoter and repressor via different cell signaling in tumor pathogenesis. </plain></SENT>
<SENT sid="315" pm="."><plain>To find the role of MRC2 on the TGFβ1 paradox about HCC progression, we treated Huh7 cells with TGFβ1 and found that cell mobility and invasion were enhanced as respected. </plain></SENT>
<SENT sid="316" pm="."><plain>However, after knockdown of MRC2 by siRNAs, the migration and invasion abilities of Huh7 cells were not affected by TGFβ1 treatment. </plain></SENT>
<SENT sid="317" pm="."><plain>These data proved strongly that MRC2 took an important part in the oncogenic function of TGFβ1 in HCC. </plain></SENT>
</text></p><p><text><SENT sid="318" pm="."><plain>In summary, this investigation showed that MRC2 expression was aberrantly increased in HCC and associated with intrahepatic metastases and portal vein invasion. </plain></SENT>
<SENT sid="319" pm="."><plain>Additionally, a high level of MRC2 in HCC tissue predicted a poor outcome after liver resection. </plain></SENT>
<SENT sid="320" pm="."><plain>It was demonstrated further that MRC2 was regulated directly by TGFβ1/Smad3 and involved in the oncogenic effect of TGFβ1 in HCC. </plain></SENT>
<SENT sid="321" pm="."><plain>Detection of MRC2 expression in HCC tissues could be very feasible guidance for the diagnosis of HCC invasion and metastasis, also for prediction of outcome after liver resection. </plain></SENT>
</text></p></sec></SecTag></body><back><SecTag type="ACK_FUND"><ack><title>Acknowledgments</title><p><text4fund><text><SENT sid="322" pm="."><plain>We thank all patients who are willing to be recruited in this investigation. </plain></SENT>
<SENT sid="323" pm="."><plain>This study was supported by grants from National Natural Scientific Foundation of China (81301743 to Xin Zheng), Research Fund for the doctoral Program of High Education of China from Ministry of Education (No. 20120201120090 to Xin Zheng), Key Science and Technology Program of Shaanxi Province (No. 2014K11-01-01-21 to Xin Zheng) and the Fundamental Research Funds for the Basic Research Operating expenses Program of Central College sponsored by Xi’an Jiaotong University to Xin Zheng. </plain></SENT>
</text></text4fund></p></ack></SecTag><notes><title>Author Contributions</title><p>X.H.G. and Z.T.L. carried out the molecular genetic studies and drafted the manuscript. X.H.G. and X.Z. participated in the design of the study and performed the statistical analysis. K.S.T. performed the supplementary experiments in this study. X.Z. conceived of the study, and participated in its design and coordination and helped to draft the manuscript. All authors read and approved the final manuscript.</p></notes><notes><title>Conflicts of Interest</title><p>The authors declare no conflict of interest.</p></notes><SecTag type="REF"><ref-list><title>References</title><ref id="B1-ijms-15-15011"><text><SENT sid="324" pm="."><plain>1.RobertsL.R.GoresG.J. Hepatocellular carcinoma: Molecular pathways and new therapeutic targets Semin. </plain></SENT>
<SENT sid="325" pm="."><plain>Liver Dis. 2005 25 212 225 10.1055/s-2005-871200 15918149 </plain></SENT>
</text></ref><ref id="B2-ijms-15-15011"><text><SENT sid="326" pm="."><plain>2. ParkinD.M.BrayF.I.DevesaS.S. Cancer burden in the year 2000. </plain></SENT>
<SENT sid="327" pm="."><plain>The global picture Eur. </plain></SENT>
<SENT sid="328" pm="."><plain>J. </plain></SENT>
<SENT sid="329" pm="."><plain>Cancer 2001 37 S4 S66 10.1016/S0959-8049(01)00267-2 11602373 </plain></SENT>
</text></ref><ref id="B3-ijms-15-15011"><text><SENT sid="330" pm="."><plain>3. HotaryK.B.AllenE.D.BrooksP.C.DattaN.S.LongM.W.WeissS.J. Membrane type I matrix metalloproteinase usurps tumor growth control imposed by the three-dimensional extracellular matrix Cell 2003 114 33 45 10.1016/S0092-8674(03)00513-0 12859896 </plain></SENT>
</text></ref><ref id="B4-ijms-15-15011"><text><SENT sid="331" pm="."><plain>4. CurinoA.C.EngelholmL.H.YamadaS.S.HolmbeckK.LundL.R.MolinoloA.A.BehrendtN.NielsenB.S.BuggeT.H. Intracellular collagen degradation mediated by uPARAP/Endo180 is a major pathway of extracellular matrix turnover during malignancy J. </plain></SENT>
<SENT sid="332" pm="."><plain>Cell Biol. 2005 169 977 985 15967816 </plain></SENT>
</text></ref><ref id="B5-ijms-15-15011"><text><SENT sid="333" pm="."><plain>5. Prud’hommeG.J. Pathobiology of transforming growth factor beta in cancer, fibrosis and immunologic disease, and therapeutic considerations Lab. </plain></SENT>
<SENT sid="334" pm="."><plain>Investig. 2007 87 1077 1091 10.1038/labinvest.3700669 17724448 </plain></SENT>
</text></ref><ref id="B6-ijms-15-15011"><text><SENT sid="335" pm="."><plain>6. SilbersteinG.B.DanielC.W. Reversible inhibition of mammary gland growth by transforming growth factor-β Science 1987 237 291 293 3474783 </plain></SENT>
</text></ref><ref id="B7-ijms-15-15011"><text><SENT sid="336" pm="."><plain>7. ForresterE.ChytilA.BierieB.AakreM.GorskaA.E.Sharif-AfsharA.R.MullerW.J.MosesH.L. Effect of conditional knockout of the type II TGF-β receptor gene in mammary epithelia on mammary gland development and polyomavirus middle T antigen induced tumor formation and metastasis Cancer Res. 2005 65 2296 2302 10.1158/0008-5472.CAN-04-3272 15781643 </plain></SENT>
</text></ref><ref id="B8-ijms-15-15011"><text><SENT sid="337" pm="."><plain>8. TianF.ByfieldS.D.ParksW.T.StueltenC.H.NemaniD.ZhangY.E.RobertsA.B. Smad-binding defective mutant of transforming growth factor beta type I receptor enhances tumorigenesis but suppresses metastasis of breast cancer cell lines Cancer Res. 2004 64 4523 4530 10.1158/0008-5472.CAN-04-0030 15231662 </plain></SENT>
</text></ref><ref id="B9-ijms-15-15011"><text><SENT sid="338" pm="."><plain>9. LiH.WangH.WangF.GuQ.XuX. Snail involves in the transforming growth factor β-mediated epithelial-mesenchymal transition of retinal pigment epithelial cells PLoS One 2011 6 e23322 21853110 </plain></SENT>
</text></ref><ref id="B10-ijms-15-15011"><text><SENT sid="339" pm="."><plain>10. MaitahM.Y.AliS.AhmadA.GadgeelS.SarkarF.H. Up-regulation of sonic hedgehog contributes to TGF-β1-induced epithelial to mesenchymal transition in NSCLC cells PLoS One 2011 6 e16068 21249152 </plain></SENT>
</text></ref><ref id="B11-ijms-15-15011"><text><SENT sid="340" pm="."><plain>11. ZhengX.VittarN.B.GaiX.Fernandez-BarrenaM.G.MoserC.D.HuC.AlmadaL.L.McCleary-WheelerA.L.ElsawaS.F.VrabelA.M. The transcription factor GLI1 mediates TGFβ1 driven EMT in hepatocellular carcinoma via a SNAI1-dependent mechanism PLoS One 2012 7 e49581 10.1371/journal.pone.0049581 23185371 </plain></SENT>
</text></ref><ref id="B12-ijms-15-15011"><text><SENT sid="341" pm="."><plain>12. WakefieldL.M.RobertsA.B. TGF-β signaling: Positive and negative effects on tumorigenesis Curr. </plain></SENT>
<SENT sid="342" pm="."><plain>Opin. </plain></SENT>
<SENT sid="343" pm="."><plain>Genet. </plain></SENT>
<SENT sid="344" pm="."><plain>Dev. 2002 12 22 29 10.1016/S0959-437X(01)00259-3 11790550 </plain></SENT>
</text></ref><ref id="B13-ijms-15-15011"><text><SENT sid="345" pm="."><plain>13. DerynckR.AkhurstR.J.BalmainA. TGF-β signaling in tumor suppression and cancer progression Nat. </plain></SENT>
<SENT sid="346" pm="."><plain>Genet. 2001 29 117 129 10.1038/ng1001-117 11586292 </plain></SENT>
</text></ref><ref id="B14-ijms-15-15011"><text><SENT sid="347" pm="."><plain>14. PardaliK.MoustakasA. Actions of TGF-β as tumor suppressor and pro-metastatic factor in human cancer Biochim. </plain></SENT>
<SENT sid="348" pm="."><plain>Biophys. </plain></SENT>
<SENT sid="349" pm="."><plain>Acta 2007 1775 21 62 16904831 </plain></SENT>
</text></ref><ref id="B15-ijms-15-15011"><text><SENT sid="350" pm="."><plain>15. EngelholmL.H.IngvarsenS.JurgensenH.J.HilligT.MadsenD.H.NielsenB.S.BehrendtN. The collagen receptor uPARAP/Endo180 Front Biosci. 2009 14 2103 2114  </plain></SENT>
</text></ref><ref id="B16-ijms-15-15011"><text><SENT sid="351" pm="."><plain>16. BehrendtN. The urokinase receptor (uPAR) and the uPAR-associated protein (uPARAP/Endo180): Membrane proteins engaged in matrix turnover during tissue remodeling Biol. </plain></SENT>
<SENT sid="352" pm="."><plain>Chem. 2004 385 103 136 10.1515/BC.2004.031 15101555 </plain></SENT>
</text></ref><ref id="B17-ijms-15-15011"><text><SENT sid="353" pm="."><plain>17. PalmieriC.CaleyM.P.PurshouseK.FonsecaA.V.Rodriguez-TejaM.KogianniG.WoodleyL.OdendaalJ.ElliottK.WaxmanJ. Endo180 modulation by bisphosphonates and diagnostic accuracy in metastatic breast cancer Br. </plain></SENT>
<SENT sid="354" pm="."><plain>J. </plain></SENT>
<SENT sid="355" pm="."><plain>Cancer 2013 108 163 169 10.1038/bjc.2012.540 23257899 </plain></SENT>
</text></ref><ref id="B18-ijms-15-15011"><text><SENT sid="356" pm="."><plain>18. WienkeD.DaviesG.C.JohnsonD.A.SturgeJ.LambrosM.B.SavageK.ElsheikhS.E.GreenA.R.EllisI.O.RobertsonD. The collagen receptor Endo180 (CD280) is expressed on basal-like breast tumor cells and promotes tumor growth in vivo Cancer Res. 2007 67 10230 10240 10.1158/0008-5472.CAN-06-3496 17974964 </plain></SENT>
</text></ref><ref id="B19-ijms-15-15011"><text><SENT sid="357" pm="."><plain>19. KogianniG.WalkerM.M.WaxmanJ.SturgeJ. Endo180 expression with cofunctional partners MT1-MMP and uPAR-uPA is correlated with prostate cancer progression Eur. </plain></SENT>
<SENT sid="358" pm="."><plain>J. </plain></SENT>
<SENT sid="359" pm="."><plain>Cancer 2009 45 685 693 10.1016/j.ejca.2008.11.023 19112015 </plain></SENT>
</text></ref><ref id="B20-ijms-15-15011"><text><SENT sid="360" pm="."><plain>20. SulekJ.Wagenaar-MillerR.A.ShiremanJ.MolinoloA.MadsenD.H.EngelholmL.H.BehrendtN.BuggeT.H. Increased expression of the collagen internalization receptor uPARAP/Endo180 in the stroma of head and neck cancer J. </plain></SENT>
<SENT sid="361" pm="."><plain>Histochem. </plain></SENT>
<SENT sid="362" pm="."><plain>Cytochem. 2007 55 347 353 17189524 </plain></SENT>
</text></ref><ref id="B21-ijms-15-15011"><text><SENT sid="363" pm="."><plain>21. ZhengX.YaoY.XuQ.TuK.LiuQ. Evaluation of glioma-associated oncogene 1 expression and its correlation with the expression of sonic hedgehog, E-cadherin and S100a4 in human hepatocellular carcinoma Mol. </plain></SENT>
<SENT sid="364" pm="."><plain>Med. </plain></SENT>
<SENT sid="365" pm="."><plain>Rep. 2010 3 965 970 21472341 </plain></SENT>
</text></ref><ref id="B22-ijms-15-15011"><text><SENT sid="366" pm="."><plain>22. ZhengX.GaiX.DingF.LuZ.TuK.YaoY.LiuQ. Histone acetyltransferase PCAF up-regulated cell apoptosis in hepatocellular carcinoma via acetylating histone H4 and inactivating AKT signaling Mol. </plain></SENT>
<SENT sid="367" pm="."><plain>Cancer 2013 12 96 10.1186/1476-4598-12-96 23981651 </plain></SENT>
</text></ref><ref id="B23-ijms-15-15011"><text><SENT sid="368" pm="."><plain>23. WienkeD.MacFadyenJ.R.IsackeC.M. Identification and characterization of the endocytic transmembrane glycoprotein Endo180 as a novel collagen receptor Mol. </plain></SENT>
<SENT sid="369" pm="."><plain>Biol. </plain></SENT>
<SENT sid="370" pm="."><plain>Cell 2003 14 3592 3604 10.1091/mbc.E02-12-0814 12972549 </plain></SENT>
</text></ref><ref id="B24-ijms-15-15011"><text><SENT sid="371" pm="."><plain>24. HuijbersI.J.IravaniM.PopovS.RobertsonD.Al-SarrajS.JonesC.IsackeC.M. A role for fibrillar collagen deposition and the collagen internalization receptor endo180 in glioma invasion PLoS One 2010 5 e9808 20339555 </plain></SENT>
</text></ref><ref id="B25-ijms-15-15011"><text><SENT sid="372" pm="."><plain>25. CaleyM.P.KogianniG.AdamarekA.GronauJ.H.Rodriguez-TejaM.FonsecaA.V.MauriF.SandisonA.RhimJ.S.PalmieriC. TGFβ1-Endo180-dependent collagen deposition is dysregulated at the tumour-stromal interface in bone metastasis J. </plain></SENT>
<SENT sid="373" pm="."><plain>Pathol. 2012 226 775 783 10.1002/path.3958 22072289 </plain></SENT>
</text></ref></ref-list></SecTag></back></article>
